drugset
drugset / Trial / NCT04606381

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

NCT04606381 ↗

Phase 1 Active not recruiting 158 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.

Timeline

Start
2020-11-10
Primary completion
2024-07-11
Completion
2027-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amivantamab Monoclonal antibody — Subcutaneous
Background rHuPH20 Protein / enzyme biologic — Subcutaneous

Indications

neoplasm